TīmeklisThe approval was based on the ELARA trial (NCT03568461), a multicenter, single-arm, open-label trial evaluating tisagenlecleucel, a CD19-directed chimeric antigen … Tīmeklis2024. gada 24. aug. · Earlier this year, Novartis reported that the primary analysis of the Phase II ELARA trial of Kymriah showed a complete response rate of 66% in relapsed or refractory follicular lymphoma patients. The company is now working towards regulatory filings of the drug for follicular lymphoma in the second half of this year.
ELARA: tisa-cel in R/R follicular lymphoma - YouTube
Tīmeklis2024. gada 26. maijs · Here we introduce ELARA, a phase 2 study evaluating the efficacy and safety of tisagenlecleucel in patients with r/r FL. Methods: ELARA is a phase 2, single-arm, multicenter, open label trial. Eligible patients must be ≥18 years of age, have radiographically measurable grade 1, 2, or 3A r/r FL that is refractory to a … Tīmeklis2015. gada 6. maijs · Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2024 Dec;20(12):1710-1718. doi: 10.1016/S1470-2045(19)30493-0. Epub 2024 Oct 9. dポイント 入金 反映されない
KYMRIAH® (tisagenlecleucel) for Follicular Lymphoma HCP
Tīmeklis2024. gada 3. jūn. · Three patients died from progressive disease and no deaths were treatment related. Kymriah was administered in the outpatient setting for 18% of … Tīmeklis2024. gada 2. jūn. · ELARA is a Phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of Kymriah in adult patients with r/r FL. This … TīmeklisKYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory (r/r) follicular … dポイント 兄弟